Research graph
References from Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study. Local targets link to admitted publications; unresolved targets remain external evidence.
